3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Squamous Cell Carcinoma of Head and Neck
639
Head and Neck Neoplasms
613
Carcinoma, Non-Small-Cell Lung
203
Thyroid Neoplasms
201
Melanoma
146
Nasopharyngeal Carcinoma
136
Oropharyngeal Neoplasms
130
Colorectal Neoplasms
130
Mouth Neoplasms
128
Neoplasms
113
Breast Neoplasms
113
Lung Neoplasms
107
Ovarian Neoplasms
105
Uterine Cervical Neoplasms
101
Neoplasm Metastasis
93
Carcinoma, Squamous Cell
87
Stomach Neoplasms
84
Carcinoma, Renal Cell
84
Triple Negative Breast Neoplasms
79
Pancreatic Neoplasms
72
Esophageal Neoplasms
70
Laryngeal Neoplasms
68
Endometrial Neoplasms
67
Urinary Bladder Neoplasms
61
Sarcoma
58
Prostatic Neoplasms
55
Thyroid Cancer, Papillary
54
Salivary Gland Neoplasms
49
Carcinoma, Transitional Cell
47
Carcinoma, Hepatocellular
46
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Head & Neck
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled